Spotlight on Ixekizumab for the Treatment of Moderate-To-Severe Plaque Psoriasis: Design, Development, and Use in Therapy

Drug Design, Development and Therapy - New Zealand
doi 10.2147/dddt.s92128
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Cost Per Responder for Ixekizumab and Other Biologic Drugs Approved for the Treatment of Moderate-To-Severe Plaque Psoriasis in Italy

Global and Regional Health Technology Assessment
Health Policy
2019English

Ixekizumab Efficacy and Safety in Moderate-To-Severe Genital Psoriasis

British Journal of Dermatology
DermatologyMedicine
2018English

Costs of Treatment in Patients With Moderate to Severe Plaque Psoriasis

Archives of Dermatology
2004English

540 Rapid Response in PASI, sPGA, and BSA Measures for Patients With Moderate-To-Severe Plaque Psoriasis With Ixekizumab

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis

JAMA Dermatology
DermatologyMedicine
2020English

Pss32 - Cost-Effectiveness of Brodalumab for the Treatment of Moderate to Severe Plaque Psoriasis in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Novel Topical Therapy for Mild-To-Moderate Plaque Psoriasis: Focus on Calcitriol

Clinical, Cosmetic and Investigational Dermatology
Dermatology
2009English

Ixekizumab: Targeting Plaque Psoriasis and Psoriatic Arthritis

Prescriber
Pharmacology
2019English

The Experience of Pain and Redness in Patients With Moderate to Severe Plaque Psoriasis

Journal of Dermatological Treatment
Dermatology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy